Pulmonary function treatment
A method of treating reduced pulmonary function by administering an effective dose of a Farnesoid X Receptor (FXR) agonist, particularly obeticholic acid, is disclosed. Also disclosed is an in vivo animal model of lung injury and altered functioning, useful for identifying compounds active in restoring pulmonary function.
1. A method of reducing alveolar epithelial wall thickening and improving pulmonary function in a patient suffering therefrom, the method comprising administering a dose of an Farsenoid X Receptor (FXR) agonist to said patient, comprising an amount of said agonist that is effective to reduce said alveolar epithelial wall thickening in said patient, wherein the FXR agonist is not an agonist for other receptors.
2. The method of claim 1 , wherein the FXR agonist comprises obeticholic acid or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
3. The method of claim 1 , wherein the reduced pulmonary function results from chemical injury to the lungs.
4. The method of claim 3 , wherein the chemical injury results from exposure to a nitrogen mustard or a sulfur mustard.
5. A method of reducing circularization of the alveolar space and improving pulmonary function in a patent suffering therefrom, the method comprising administering a dose of an FXR agonist to said patient subj-eet, wherein said dose is effective to reduce circularization of the alveolar space and increase lung mechanics and improve oxygen/CO2 exchange in said patient wherein the FXR agonist is not an agonist for other receptors.
6. The method of claim 5 , wherein the FXR agonist composition comprises obeticholic acid, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.
7. The method of claim 5 , wherein the diminished pulmonary function is due to the toxic effect of at least one of a vesicant and/or a highly toxic chemical.
8. The method of claim 7 , wherein the highly toxic chemical is selected from corrosive gases, strong acids, strong bases, dehydrating corrosives and corrosive solids.
9. The method of claim 7 , wherein the vesicant is selected from the group consisting of distilled mustard, mustard gas, lewisite, mustard/lewisite, mustard/T, nitrogen mustard, sesqui mustard, sulfur mustard, phosgene oxime and cantharidin.
10. The method of claim 8 , wherein the corrosive gas is selected from the group consisting of hydrogen sulfide, hydrogen fluoride, hydrogen chloride, hydrogen bromide, hydrogen cyanide, arsine, phosphine, nitric oxide, nitrogen dioxide, sulfur dioxide, ozone, chlorine, methylamine, and ammonia.
11. The method of claim 8 , wherein the strong acid is selected from the group consisting of hydrochloric acid, sulfuric acid, and phosphoric acid.
12. The method of claim 8 , wherein the strong base is selected from the group consisting of sodium hydroxide, potassium hydroxide and aqueous ammonia.
13. The method of claim 8 , wherein the strong dehydrating corrosive is selected from the group consisting of concentrated sulfuric acid, phosphorous pentoxide and calcium oxide.
14. The method of claim 8 , wherein the corrosive solid is selected from phosphorous and phenol.
15. The method of claim 5 , wherein the effective amount of FXR agonist composition is administered to the patient before or while the patient is exposed to a vesicant or a corrosive gas, or after the patient has been exposed to at least one of a vesicant and/or a corrosive gas.
16. The method of claim 5 , wherein the toxic effect is characterized by diminished pulmonary function induced by at least one of a vesicant and/or a highly toxic chemical.
17. The method of claim 5 , wherein the effective amount of the FXR agonist composition is administered to the patient by oral, intravenous, intramuscular, intracutaneous, subcutaneous injection, oral respiratory or nasal route.
18. The method of claim 5 , wherein the effective amount of the FXR agonist is about 1 to about 100 mg.
19. The method of claim 1 , wherein said alveolar epithelial wall thickening is not caused by a lung disease.
20. The method of claim 5 , wherein said circularization of the alveolar space is not caused by a lung disease.